World Leading Drug Formulation Specialist MedPharm Ltd Opens U.S. Facility In Research Park Triangle To Service Growing Dermatology Market
RTP, September 28, 2016:?MedPharm (www.medpharm.co.uk), the world leading topical and transdermal drug formulation development specialist yesterday officially opened its new USA based subsidiary; MP Pharma Services Inc. Already the first client studies have been completed on-site following full equipment and process validation.
“Our new laboratories enable pharmaceutical companies to test various topical and transdermal formulations such as creams, gels and sprays for both new and existing drugs” says Professor Marc Brown, Cofounder and CSO: “Over the last 20 years, MedPharm has established an undisputed leadership position in topical and transdermal formulation development. We have built strong relationships with many of the major US pharmaceutical players and this major investment will enable us to provide our clients with an even faster response to their development challenges, whether it is for new chemical entities, reformulation, generics or claim substantiation.”
Dr. Jon Lenn, VP MedPharm US says “I am excited to have joined MedPharm with its high level of scientific rigor and new US laboratories in RTP, NC. We are looking forward to offering clients a host of innovative biological models and automated systems that will greatly de-risk and expedite their development programs.”
The facility will provide clients with access to MedPharm’s unique and novel in vitro models. These allow assessment of new drug candidate libraries and formulation performance through efficacy, target engagement and delivery testing in quicker and more reliable ways than previously possible.
“This is an exciting milestone for MedPharm. Adding local capacity and bringing on board new proprietary testing models and high through-put screens, will give our North and South American clients the best opportunity yet of reaching the market with the innovative products we help develop for them,” commented Dr Andrew Muddle, Cofounder and CEO.
Notes to editors?
?MedPharm is the leading topical and transdermal pharmaceutical development company. It is recognised internationally for its expertise in transdermal and topical (skin, nail, nose, lungs and other mucosal membranes) formulations and drug delivery systems. Initiated in 1996, MedPharm has built a worldwide reputation for its unique and highly specialized service in contract research, development and manufacturing. The company offers a complete suite of development options from simple feasibility tests, formulation and dosage form design, optimisation and testing through to preparation of GMP investigational products for use in clinical trials world-wide. MedPharm is unique in that its proprietary in-vitro models are the only ones to have been recognised by the regulators as suitable surrogates for clinical trials. The company operates a hybrid business model, with a CRO business and a development programme with a substantial patent portfolio of novel topical and transdermal drug delivery systems including MedSpray®, MedRo® and AquaRMed™. It has produced these innovations by exploiting its internal product development expertise. MedPharm’s laboratories in the UK are routinely inspected by Regulatory Authorities and are certified for GMP and GLP studies.?
“Our new laboratories enable pharmaceutical companies to test various topical and transdermal formulations such as creams, gels and sprays for both new and existing drugs” says Professor Marc Brown, Cofounder and CSO: “Over the last 20 years, MedPharm has established an undisputed leadership position in topical and transdermal formulation development. We have built strong relationships with many of the major US pharmaceutical players and this major investment will enable us to provide our clients with an even faster response to their development challenges, whether it is for new chemical entities, reformulation, generics or claim substantiation.”
Dr. Jon Lenn, VP MedPharm US says “I am excited to have joined MedPharm with its high level of scientific rigor and new US laboratories in RTP, NC. We are looking forward to offering clients a host of innovative biological models and automated systems that will greatly de-risk and expedite their development programs.”
The facility will provide clients with access to MedPharm’s unique and novel in vitro models. These allow assessment of new drug candidate libraries and formulation performance through efficacy, target engagement and delivery testing in quicker and more reliable ways than previously possible.
“This is an exciting milestone for MedPharm. Adding local capacity and bringing on board new proprietary testing models and high through-put screens, will give our North and South American clients the best opportunity yet of reaching the market with the innovative products we help develop for them,” commented Dr Andrew Muddle, Cofounder and CEO.
Notes to editors?
?MedPharm is the leading topical and transdermal pharmaceutical development company. It is recognised internationally for its expertise in transdermal and topical (skin, nail, nose, lungs and other mucosal membranes) formulations and drug delivery systems. Initiated in 1996, MedPharm has built a worldwide reputation for its unique and highly specialized service in contract research, development and manufacturing. The company offers a complete suite of development options from simple feasibility tests, formulation and dosage form design, optimisation and testing through to preparation of GMP investigational products for use in clinical trials world-wide. MedPharm is unique in that its proprietary in-vitro models are the only ones to have been recognised by the regulators as suitable surrogates for clinical trials. The company operates a hybrid business model, with a CRO business and a development programme with a substantial patent portfolio of novel topical and transdermal drug delivery systems including MedSpray®, MedRo® and AquaRMed™. It has produced these innovations by exploiting its internal product development expertise. MedPharm’s laboratories in the UK are routinely inspected by Regulatory Authorities and are certified for GMP and GLP studies.?